Background: The serum GH cut-off value for pharmacological tests of GH secretion (PhT GH) depends on the type of test and also on the method used for determining serum GH. Cut-off serum GH values as different as 5–10 ng/ml, have been reported, and have been validated biochemically. We have used the growth velocity (GV)-standard deviation score (SDS) during the first year of treatment with rhGH to validate these cut-offs on a biological basis. Methods: Fifty pre-pubertal patients with short stature (height ≤–2 SDS and GV ≤–1.2 SDS) were studied. GH deficiency (GHD) was diagnosed in 39 patients, on the basis of clinical and auxological parameters and on the serum concentration of IGF-1, and non-GHD in the other 11 patients. Two PhT GH (arginine and clonidine) were carried out in the 50 patients. Serum GH was determined by two different methods: one detecting most of serum GH isoforms, named Total GH (HGH Bio-Tech, MAIA Clone), and another one, only detecting the 22 kDa GH, named 22K GH (GH-22K IFMA, Wallac). Results: Basal data: all patients with GHD and with non-GHD had maximal serum GH response (MaxR) values below and above the cut-off, respectively, for the serum Total GH and 22K GH. The mean 22K GH/Total GH ratio was similar to previous publications. Post-rhGH treatment data: the two groups improved their height SDS during the first year of treatment, particularly patients with GHD. A receiver-operator curve was used to define the best threshold for post-treatment GV-SDS that separates GHD from non-GHD patients. This value was 1.91 GV-SDS. A negative correlation between first year treatment GV-SDS and pre-treatment serum GH MaxR was found for the two assays (p < 0.001). Then, the best cut-off GV-SDS, previously calculated with the receiver-operator curve (1.91 SDS) was used to interpolate the corresponding serum GH values, as determined by the two methods. For Total GH, the value was 10.8 ng/ml, and for 22K GH, it was 5.4 ng/ml. Conclusion: The cut-off values calculated by biological means to separate GHD from non-GHD were remarkably similar to those calculated biochemically (10.0 and 4.8 ng/ml, respectively) for Total and 22K GH. This is a biological validation for using different cut-off values, appropriate for each assay, to diagnose GHD.

Keywords:
Serum growth hormone, GH pharmacological tests, Serum GH cut-off, GH deficiency, Idiopathic short stature
1.
Baumann G: Growth hormone heterogeneity: genes, iso-hormones, variants, and binding proteins. Endocr Rev 1991;12:424–449.
2.
Popii V, Baumann G: Laboratory measurement of growth hormone. Clin Chim Acta 2004;350:1–16.
3.
Wood P: Growth hormone: its measurement and the need for assay harmonization. Ann Clin Biochem 2001;38:471–482.
4.
Chaler E, Belgorosky A, Maceiras M, Mendioroz M, Rivarola MA: Between-assay differences in serum GH measurements: importance in the diagnosis of GH deficiency in childhood. Clin Chem 2001;47:1735–1738.
5.
GH Research Society: 2000 Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 2000;85:3990–3993.
6.
Boquete HR, Sobrado PG, Fideleff HL, Sequeira AM, Giaccio AV, Suarez MG, Rubial G, Miras M: Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. J Clin Endocrinol Metab 2003;88:4702–4708.
7.
Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wickland W, Price DA: Derivation and validation of a mathematical model for predicting the response to exogenous recombinant growth hormone (GH) in prepubertal children with idiopathic GH deficiency. J Clin Endocrinol Metab 1999;84:1174–1183.
8.
Lejarraga H, Orfila G: Estándares de peso y estatura para niñas y niños argentinos desde el nacimiento hasta la madurez. Arch Argent Pediatr 1987;85:209–222.
9.
Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170–179.
10.
Greulich WW, Pile SI (Eds): Radiographic Atlas of Skeletal Development of the Hand and Wrist. Standford, Standford University Press, 1959.
11.
Albertsson-Wickland K, Jansson C, Rosberg S, Novamo A: Time-resolved immunofluorometric assay of human growth hormone. Clin Chem 1993;39:1620–1625.
12.
Rivarola MA, Mendilaharzu H, Warman M, Belgorosky A, Iorcansky, Castellano, Caresana A, Chaler E, Maceiras M: Endocrine disorders in 66 suprasellar and pineal tumors of patients with prepubertal and pubertal ages. Horm Res 1992;37:1–6.
13.
Bozzola M, Zecca M, Locatelli F, Radetti G, Pagani S, Aurelli M, Tato L, Chatelain P: Evaluation of Growth hormone bioactivity using the Nb2 cell bioassay in children with growth disorders. J Endocrinol Invest 1998;21:765–770.
14.
Chaler E, Travaglino P, Pagani S, Bozzola E, Marino R, Berensztein E, Maceiras M, Tauber M, Rivarola MA, Belgorosky A, Bozzola M: Dose dependency of the serum Bio/Immuno GH ratio in children during pharmacological secretion tests. J Endocrinol Invest 2006;29:109–114.
15.
Marino R, Chaler EA, Warman M, Ciaccio M, Berensztein E, Rivarola MA, Belgorosky A: The serum growth hormone (GH) response to provocative tests is dependent on type of assay inautosomal dominant isolated GH deficiency because an ARG(183)HIS (R183H) GH-1 gene mutation. Clin Chem 2003;49:1002–1005.
16.
Ciaccio M, Belgorosky A, Rivarola MA: Differences in serum insulin-like growth factor I and sex-hormone-binding globulin levels between late and early prepuberty in patients with idiopathic and organic growth hormone deficiency. Acta Endocrinol (Copenh) 1993;129:419–423.
17.
Belgorosky A, Rivarola MA: Insulin-like growth factor binding protein (IGFBP)-3 bound IGF-I and IGFBP-3 bound IGF-II in growth hormone deficiency. Horm Res 1999;52:60–65.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.